Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 4

Conditions

Carcinoma, Hepatocellular 9Squamous Cell Carcinoma of Head and Neck 4Nasopharyngeal Carcinoma 4Esophageal Squamous Cell Carcinoma 4Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Pancreatic Neoplasms 2Locally Advanced Rectal Cancer 2Colonic Neoplasms 2Cervical Cancer Metastatic 2Breast Neoplasms 2Adenocarcinoma 2Turcot syndrome 1Salivary Gland Neoplasms 1Recurrence 1Rectal Cancer Patients 1Non-squamous Non-small-cell Lung Cancer 1Mouth Neoplasms 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Laryngeal Neoplasms 1Gestational Trophoblastic Disease 1Esophageal Squamour Cell Cancer 1Endometrioid Endometrial Cancer 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1Advanced Primary Liver Cancer 1

Interventions

Cisplatin 32Gemcitabine 21Radiotherapy, Intensity-Modulated 16toripalimab 14Capecitabine 11Magnetic Resonance Spectroscopy 10Specimen Handling 9Radiotherapy 7Drug Therapy 7pembrolizumab 6Platinum 6Nivolumab 6Immune Checkpoint Inhibitors 61,2-diaminocyclohexaneplatinum II citrate 6Docetaxel 5tislelizumab 4spartalizumab 4camrelizumab 4sintilimab 3anlotinib 3Immunoglobulin G 3Disulfides 3Carboplatin 3nimotuzumab 2fludarabine 2atezolizumab 2Taxes 2Radiation 2Phantoms, Imaging 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × camrelizumab × 1 year × Clear all
NCT05524168 2026-05-07

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 2 Active not recruiting
41 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT04944914 2026-04-30

Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 3 Recruiting
188 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT07555860 2026-04-29

Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 2 Not yet recruiting
28 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT06239727 2026-03-06

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Sun Yat-sen University

Phase 3 Recruiting
593 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡